You might also like
Cerus Corporation (CERS) is a biomedical products company dedicated to enhancing the safety of the global blood supply. The company develops and commercializes the INTERCEPT Blood System, a proprietary technology designed to reduce blood-borne pathogens and donor leukocytes in blood components intended for transfusion. Cerus operates globally, selling its products in regions such as the United States, Europe, the Middle East, and Latin America, with a focus on pathogen reduction in platelets, plasma, and red blood cells.
-
INTERCEPT Blood System for Platelets and Plasma - Reduces pathogens in platelets and plasma to ensure safer transfusions. Approved by the FDA in the U.S. and certified in the EU, it is marketed globally.
- Disposable Kits - Used for pathogen reduction during blood processing.
- UVA Illumination Devices - Supports the pathogen reduction process.
- Maintenance Services - Includes spare parts and storage solutions for illuminators.
-
INTERCEPT Blood System for Cryoprecipitation - Produces INTERCEPT Fibrinogen Complex (IFC) for treating bleeding disorders and pathogen-reduced plasma, cryoprecipitate reduced. Approved by the FDA for use in the U.S..
-
INTERCEPT Blood System for Red Blood Cells - Currently in development, this system is undergoing Phase 3 clinical trials in the U.S. and has a pending CE Certificate of Conformity application in the EU. It aims to reduce pathogens in red blood cells for transfusion.
- With your gross margins expected to remain relatively stable near current levels, what specific strategies do you have to significantly improve margins moving forward?
- Given that a significant portion of your R&D expenses are funded by BARDA, how are you preparing for potential fluctuations in government funding, and what steps are you taking to mitigate risks associated with this dependency?
- Considering the anticipated regulatory approval of the LED illuminator in Europe in 2025 and the PMA submission in the U.S. in 2026, how does this timeline affect your competitive positioning, and what measures are you taking to address any potential market challenges?
- As demand for INTERCEPT Fibrinogen Complex (IFC) grows, do you anticipate any manufacturing capacity constraints, and how might these impact your ability to meet customer demand and revenue growth targets?
- With the completion of the ReCePI trial and the planned conclusion of the RedeS trial, how do you plan to offset the potential decrease in government contract revenue and sustain growth in this area?